Advertisement
J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1194/jlr.R800036-JLR200 on October 27, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
R800036-JLR200v1
50/Supplement/S145    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Navab, M.
Right arrow Articles by Fogelman, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Navab, M.
Right arrow Articles by Fogelman, A. M.
Related Collections
Right arrow Related Webpages
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of Lipid Research, Vol. 50, S145-S149, April 2009
Copyright © 2009 by American Society for Biochemistry and Molecular Biology

Lipoprotein Metabolism

The role of dysfunctional HDL in atherosclerosis

Mohamad Navab1,*, Srinivasa T. Reddy*, Brian J. Van Lenten*, G. M. Anantharamaiah{dagger} and Alan M. Fogelman*

* Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1679
{dagger} Atherosclerosis Research Unit, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294

This work was supported in part by US Public Health Service grants HL-30568 and HL-34343 and the Laubisch, Castera, and M.K. Grey Funds at UCLA. M.N., S.T.R., G.M.A. and A.M.F. are principals in Bruin Pharma and A.M.F. is an officer in Bruin Pharma.

Published, JLR Papers in Press, October 27, 2008.

1 To whom correspondence should be addressed. e-mail: mnavab{at}mednet.ucla.edu


ABSTRACT

This review focuses on HDL function in modulating LDL oxidation and LDL-induced inflammation. Dysfunctional HDL has been identified in animal models and humans with chronic inflammatory diseases including atherosclerosis. The loss of antiinflammatory function correlated with a loss of function in reverse cholesterol transport. In animal models and perhaps in humans, dysfunctional HDL can be improved by apoA-I mimetic peptides that bind oxidized lipids with high affinity.

Supplementary key words inflammation • high density lipoprotein • LDL • mimetic peptides • L-4F • D-4F

Abbreviations: apo, apolipoprotein; CHD, coronary heart disease; HII, HDL-inflammatory index; HPETE, hydroperoxyeicosatetraenoic acid; HPODE, hydroperoxyoctadecadienoic acid; 12-LO, 12-lipoxygenase; MCP-1, monocyte chemoattractant-1; PAPC, 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine; PON, paraoxonase


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


Related Webpages:

JLR 50th Anniversary Collections
Anniversary Collection::Lipoprotein Metabolism

This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
A. Undurti, Y. Huang, J. A. Lupica, J. D. Smith, J. A. DiDonato, and S. L. Hazen
Modification of High Density Lipoprotein by Myeloperoxidase Generates a Pro-inflammatory Particle
J. Biol. Chem., November 6, 2009; 284(45): 30825 - 30835.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2009 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement